Amicus Therapeutics Inc (LTS:0HF9)
$ 9.978 -0.0808 (-0.8%) Market Cap: 2.98 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 16.66 GF Score: 81/100

Amicus Therapeutics Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript

Sep 18, 2020 / 03:45PM GMT
Release Date Price: $10.19
Bradley L. Campbell
Amicus Therapeutics, Inc. - President, COO & Director

(technical difficulty)

The development for Pompe disease, and that's slated to read out early next year. And then we have a broad gene therapy pipeline, importantly, 2 clinical-stage programs in CLN6 and CLN3 Batten disease and a number of additional programs in preclinical development. And in such a strange year, it has been this year, it's been a great year so far for Amicus, even in the face of COVID and the global pandemic. Galafold, as I mentioned, is on track from a revenue perspective. Our Pompe program, we've been able to maintain the integrity of that study and really looking forward to seeing that readout and continue to progress the other programs as well.

So for the first half of the year, we've seen strong performance in our business and across our business and look forward to continued performance in the months ahead.

Questions & Answers

Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Okay. Great. So let's dive into some detailed

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot